Physician profile
John Knecht
NPI 1639360829
$88,906.52
in general payments reported to CMS, 2019-2025
74 companies · $9,083 in 2025
The $9,083 reported for 2025 was more than what 80% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $19K · 2021: $12K · 2022: $5,888 · 2023: $6,796 · 2024: $4,491 · 2025: $9,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $6,053 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,912.96 |
| Consulting Fee | $6,053.00 |
| Education | $403.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $55,135.91 | 2019-2025 | Jakafi, Monjuvi, Monjuvi |
| Astrazeneca Pharmaceuticals Lp | $5,087.80 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Regeneron Pharmaceuticals, INC. | $2,588.00 | 2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $2,254.16 | 2023-2025 | Fotivda |
| Novartis Pharmaceuticals Corporation | $2,153.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,128.03 | 2019-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $1,697.09 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $1,530.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $1,370.05 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $1,091.91 | 2019-2025 | |
| Astellas Pharma US INC | $1,088.68 | 2020-2025 | Padcev, Xtandi, Vyloy |
| Janssen Biotech, INC. | $936.28 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Lilly USA, LLC | $819.81 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Seagen INC. | $765.08 | 2019-2025 | |
| Celgene Corporation | $724.31 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $678.49 | 2021-2024 | Brukinsa |
| Abbvie INC. | $543.42 | 2021-2025 | |
| Taiho Oncology, INC. | $400.95 | 2021-2025 | |
| Sobi, INC | $400.28 | 2022-2025 | |
| Genentech USA, INC. | $376.29 | 2022-2024 | Lunsumio, Tecentriq |
| Rigel Pharmaceuticals, INC. | $360.51 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $354.65 | 2021-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $353.80 | 2022-2025 | Fruzaqla |
| Amgen INC. | $349.01 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $338.04 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $336.75 | 2021-2023 | Monoferric |
| Eisai INC. | $329.33 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $269.02 | 2022-2024 | Ultomiris |
| Genzyme Corporation | $263.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.34 | 2019-2024 | Gilotrif |
| Emd Serono, INC. | $249.78 | 2023-2025 | Bavencio |
| Puma Biotechnology, INC. | $231.46 | 2020-2025 | |
| Exelixis INC. | $220.46 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $217.65 | 2024-2025 | Orgovyx |
| Janssen Pharmaceuticals, INC | $196.83 | 2019-2024 | Xarelto |
| Karyopharm Therapeutics INC. | $176.38 | 2022-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $155.03 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.07 | 2019-2025 | |
| Blueprint Medicines Corporation | $151.71 | 2022-2023 | Ayvakit |
| Myovant Sciences INC. | $148.86 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $140.63 | 2023-2024 | Myrisk, Mychoice Cdx |
| Pharmaessentia USA Corporation | $133.93 | 2023-2025 | Besremi |
| Recordati_rare_diseases_inc. | $124.64 | 2025 | Sylvant |
| Gilead Sciences, INC. | $120.01 | 2021-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $113.64 | 2019-2023 | Tazverik |
| Tempus Ai, INC | $109.80 | 2024 | |
| Adaptive Biotechnologies Corporation | $96.91 | 2022-2025 | Clonoseq |
| Cti Biopharma Corp. | $96.80 | 2022-2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $88.47 | 2024-2025 | Vivimusta, Danziten |
| Mirati Therapeutics, INC. | $85.10 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $73.82 | 2021-2022 | |
| Dova Pharmaceuticals | $65.08 | 2019-2021 | |
| Pharming Healthcare, INC. | $62.80 | 2024-2025 | Ruconest |
| Dendreon Pharmaceuticals LLC | $57.80 | 2022-2025 | Provenge |
| Morphosys, US INC. | $57.33 | 2021-2023 | Monjuvi |
| Menarini Silicon Biosystems, INC. | $50.97 | 2023 | Cellsearch |
| Fresenius Kabi USA, LLC | $50.01 | 2024 | Stimufend |
| Syndax Pharmaceuticals, INC. | $48.50 | 2025 | Revuforj |
| Springworks Therapeutics, INC. | $41.28 | 2024 | Ogsiveo |
| Shield Therapeutics INC | $38.11 | 2023-2025 | |
| Novo Nordisk INC | $37.93 | 2022-2024 | Novoseven |
| Tesaro, INC. | $35.67 | 2019 | |
| Servier Pharmaceuticals LLC | $35.58 | 2022 | |
| Verastem, INC. | $35.31 | 2019 | |
| Verity Pharmaceuticals INC. | $29.20 | 2025 | Trelstar |
| Deciphera Pharmaceuticals INC. | $28.16 | 2024 | Qinlock |
| Sun Pharmaceutical Industries INC. | $28.08 | 2024 | |
| Beone Medicines USA, INC. | $28.04 | 2025 | Brukinsa |
| Ucb, INC. | $24.80 | 2024 | Bimzelx |
| Almatica Pharma LLC | $24.47 | 2025 | Teriparatide |
| Stemline Therapeutics INC. | $21.29 | 2025 | Orserdu |
| Radius Health, INC. | $17.92 | 2021 | |
| Inari Medical, INC. | $14.70 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Depuy Synthes Sales INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,925.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Knecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.